Cilengitide
| Cilengitide | |
|---|---|
 |
|
|
2-[(2S,5R,8S,11S)-5-benzyl-11-{3-[(diaminomethylidene)amino]propyl}-7-methyl-3,6,9,12,15-pentaoxo-8-(propan-2-yl)-1,4,7,10,13-pentaazacyclopentadecan-2-yl]acetic acid |
|
| Identifiers | |
| CAS number | 188968-51-6 |
| PubChem | 176873 |
| ChemSpider | 154046  |
| KEGG | D03497 |
| MeSH | Cilengitide |
| ChEMBL | CHEMBL429876 |
| Jmol-3D images | Image 1 |
|
|
|
|
| Properties | |
| Molecular formula | C27H40N8O7 |
| Molar mass | 588.66 g mol−1 |
 (verify) (what is:  / ?)Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Cilengitide is a molecule designed and synthesized at the Technical University Munich in collaboration with Merck KGaA in Darmstadt. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels). Hence, it is under investigation for the treatment of glioblastoma by inhibiting angiogenesis.[1][2]
The European Medicines Agency has granted cilengitide orphan drug status.[3]
[edit] References
- ^ Burke P, DeNardo S, Miers L, Lamborn K, Matzku S, DeNardo G (2002). "Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts". Cancer Res 62 (15): 4263–72. PMID 12154028.
- ^ Goodman Simon L., Hoelzemann Guenter, Sulyok Gabor A. G., Kessler Horst (2002). "Nanomolar Small Molecule Inhibitors for αvβ6, αvβ5, and αvβ3 Integrins". Journal of Medicinal Chemistry 45 (5): 1045–51. doi:10.1021/jm0102598. PMID 11855984.
- ^ H. Spreitzer (October 27, 2008). "Neue Wirkstoffe - Cilengitide" (in German). Österreichische Apothekerzeitung (22/2008): 1136–7.
 |
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
